ASCO 2013 Intro

Article

Cancer Network and the journal ONCOLOGY present exclusive coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Visit one of our topic-specific ASCO pages or follow the stories below to catch some of the most important information to come out of this year's event.

Cancer Network and the journal ONCOLOGY present exclusive coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Visit one of our topic-specific ASCO pages or follow the stories below to catch some of the most important information to come out of this year's event.

 

• ASCO 2013 Breast Coverage

• ASCO 2013 Lung Cancer Coverage

• ASCO 2013 Prostate Cancer Coverage

Recent Videos
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.

Thyroidectomy Shows Noninferiority Without Radioiodine in Thyroid Cancer

Roman Fabbricatore
February 5th 2025
Article

A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD
February 3rd 2025
Podcast

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.

Genomic Features May Define Patient Selection in KRAS-mutated NSCLC

Roman Fabbricatore
February 4th 2025
Article

Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.

FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer

Russ Conroy
February 4th 2025
Article

Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.

Integrative Oncology Approaches to Managing Gastrointestinal Cancer

Integrative Oncology Approaches to Managing Gastrointestinal Cancer

Ariana Pelosci
February 4th 2025
Article

Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.